Cover Image
Market Research Report
Product code
192809

Retinoblastoma (Oncology) - Drugs In Development, 2021

Published: | Global Markets Direct | 84 Pages | Delivery time: 1-2 business days

Price

Back to Top
Retinoblastoma (Oncology) - Drugs In Development, 2021
Published: August 30, 2021
Global Markets Direct
Content info: 84 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Drugs In Development, 2021, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 3 and 10 respectively.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC13047IDB

Table of Contents

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Retinoblastoma - Overview
  • Retinoblastoma - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Retinoblastoma - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Retinoblastoma - Companies Involved in Therapeutics Development
  • Aileron Therapeutics Inc
  • APEIRON Biologics AG
  • Ascentage Pharma Group International
  • Canget BioTekpharma LLC
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Innovation Pharmaceuticals Inc
  • Oxular Ltd
  • PepVax Inc
  • Seneca Therapeutics Inc
  • Spectocular LLC
  • Targeted Therapy Technologies LLC
  • VCN Biosciences SL
  • Y-mAbs Therapeutics Inc
  • Retinoblastoma - Drug Profiles
  • ALRN-6924 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APG-115 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bi-specific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • conbercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Inhibit MDM2 for Retinoblastoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FL-761 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FL-7729 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FL-7N1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Kevetrin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lorukafusp alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OXU-003 SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PVX-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit MDM2 for Unspecified Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SVV-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • topotecan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VCN-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Retinoblastoma - Dormant Projects
  • Retinoblastoma - Product Development Milestones
  • Featured News & Press Releases
  • Oct 12, 2020: Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for retinoblastoma treatment
  • Jan 24, 2019: SJD Barcelona Children's Hospital is, for the first time in the world, treating a childhood cancer of the retina with the oncolytic virus VCN-01
  • Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01
  • Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
  • Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
  • Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma
  • Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma
  • Oct 31, 2012: VCN Biosciences at the 2012 Annual Meeting of the European Society of Cell & Gene Therapy in Versailles
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development for Retinoblastoma, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Retinoblastoma - Pipeline by Aileron Therapeutics Inc, 2021
  • Retinoblastoma - Pipeline by APEIRON Biologics AG, 2021
  • Retinoblastoma - Pipeline by Ascentage Pharma Group International, 2021
  • Retinoblastoma - Pipeline by Canget BioTekpharma LLC, 2021
  • Retinoblastoma - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2021
  • Retinoblastoma - Pipeline by Innovation Pharmaceuticals Inc, 2021
  • Retinoblastoma - Pipeline by Oxular Ltd, 2021
  • Retinoblastoma - Pipeline by PepVax Inc, 2021
  • Retinoblastoma - Pipeline by Seneca Therapeutics Inc, 2021
  • Retinoblastoma - Pipeline by Spectocular LLC, 2021
  • Retinoblastoma - Pipeline by Targeted Therapy Technologies LLC, 2021
  • Retinoblastoma - Pipeline by VCN Biosciences SL, 2021
  • Retinoblastoma - Pipeline by Y-mAbs Therapeutics Inc, 2021
  • Retinoblastoma - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Retinoblastoma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021